|
|
|
|
|
|
|
|
|
|
|
05.11.26 - 07:03
|
Innate Pharma Reports Third Quarter 2026 Business and Financial Update (Business Wire)
|
|
|
Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event
Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in Sézary syndrome in H2 2027
AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027
Cash position of €96.8 million1 as of September 30, 2026; anticipated cash horizon until the end of Q1 2028
Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET
MARSEILLE, France--(BUSINESS WIRE)--$IPH #ADC--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine months ended September 30, 2026.
“As we approach year-end, our strengthened cash position enables us to work towards executing the ...
|
|
|
20.10.26 - 07:03
|
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--#Biotech--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial update for the third quarter of 2026.
Participants during the call will be:
Jonathan Dickinson, Chief Executive Officer
Markus Jensen, Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Stéphanie Cornen, Vice President, Investor Relations and Communications
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Event details
Date and time: November 5, 2026 at 2:00 p.m. CET / 8:00 a.m. ET
Webcast link: Click here
Conference call link: Click here
This information is also available on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following ...
|
|
|
|
|
|
|
|
|
|
|
17.09.26 - 07:06
|
Innate Pharma Reports First Half 2026 Business Update and Financial Results (Business Wire)
|
|
|
New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027
€30 million equity financing completed to primarily support IPH4502 and preclinical ADC portfolio
IPH4502 Phase 1 dose escalation and cohort enrichment enrollment completed, with initial data to be presented at ENA 2026
PACIFIC-9 Phase 3 readout for monalizumab, led by AstraZeneca, expected in H2 2026
Cash position of €21.4 million1 as of June 30, 2026
Anticipated cash horizon until the end of Q1 2028, taking into account the initial payment of $75 million expected from the completion of the transaction with Sobi and the proceeds from the €30 million capital increase
Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. ET
MARSEILLE, France--(BUSINESS WIRE)--$IPH #ADC--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for th...
|
|
|
|
|
|
|
10.09.26 - 07:03
|
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--$IPH #ADC--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026.
Participants in the call will be:
Jonathan Dickinson, Chief Executive Officer
Markus Jensen, Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Chief Operating Officer
Frédéric Lombard, Senior Vice President, Chief Financial Officer
Event Details
Date and time: September 17, 2026, at 2:00 p.m. CEST / 8:00 a.m. EDT
Webcast link: Click here
Conference call link: Click here
This information is also available on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage ...
|
|
|
02.09.26 - 07:03
|
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
|
|
|
MARSEILLE, France--(BUSINESS WIRE)--$IPH #ADC--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor meetings at the following conference:
H.C. Wainwright 28th Annual Global Investment Conference
Dates: September 14–16, 2026
Location: New York, United States
Fireside chat:
Date: September 14, 2026
Time: 4:30 PM EDT / 10:30 PM CEST
Webcast: Access the webcast
The link to access the live webcast of the fireside chat will also be available on the Events page of the Investors section of Innate Pharma's website. A replay will be available following the event.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative targ...
|
|
|
|
|
|
|
10.08.26 - 08:39
|
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer (Business Wire)
|
|
|
Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndrome
Markus Jensen appointed Chief Medical Officer, bringing leadership continuity to execute TELLOMAK-3 and to prepare for upcoming IPH4502 development milestones
MARSEILLE, France--(BUSINESS WIRE)--$IPH #ADC--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026, succeeding Sonia Quaratino.
The planned initiation of the TELLOMAK-3 confirmatory Phase 3 study marks an important step for Innate as the Company enters a new phase of late-stage clinical an...
|
|
|
|
|
08.06.26 - 16:57
|
XETR: Deletion of Instruments from XETRA - 08.06.2026 (XETRA)
|
|
|
The following instruments on XETRA do have their last trading day on 08.06.2026.
Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 08.06.2026.
ISIN Name
US0028962076 Abercrombie & Fitch Co.
US0162551016 Align Technology Inc.
US0311001004 AMETEK Inc.
US1713401024 Church & Dwight Co. Inc.
US1729081059 Cintas Corp.
US22052L1044 Corteva Inc.
US2310211063 Cummins Inc.
US2533931026 Dicks Sporting Goods Inc.
US2910111044 Emerson Electric Co.
US30212P3038 Expedia Group Inc.
FR0004163111 Genfit S.A.
US37940X1028 Global Payments Inc.
US43300A2033 Hilton Worldwide Holdings Inc.
US45168D1046 IDEXX Laboratories Inc.
FR0010331421 Innate Pharma S.A.
US46266C1053 IQVIA Holdings Inc.
US5380341090 Live Nation Entertainment Inc.
US5719032022 Marriott International Inc.
US57667L1070 Match Group Inc.
US5926881054 Mettler-Toledo International Inc.
US5950171042 Microchip Technology Inc.
US6200763075 Motorola Solutions Inc.
US6819191064 Omnicom Group Inc.
US68902V1070 Otis Worldwi...
|
|